SGLT-2-话题@MedSci

#SGLT-2#

39篇内容 | 867人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=2081998, encodeId=abfd208199862, content=<a href='/topic/show?id=acf116218e6' target=_blank style='color:#2F92EE;'>#SGLT-2#</a>, objectTitle=Cardiovasc Diabetol：GLP-1受体激动剂与SGLT-2抑制剂在2型糖尿病的有效性和安全性, objectType=article, longId=739436, objectId=f1a5e39436f8, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f1a5e39436f8, replyNumber=0, likeNumber=41, createdTime=2023-08-28, rootId=0, userName=fmq_28614553, userId=0a3a2500014, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f1a5e39436f8, moduleTitle=Cardiovasc Diabetol：GLP-1受体激动剂与SGLT-2抑制剂在2型糖尿病的有效性和安全性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f1a5e39436f8)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2081995, encodeId=d57220819956e, content=<a href='/topic/show?id=acf116218e6' target=_blank style='color:#2F92EE;'>#SGLT-2#</a>, objectTitle=Front Pharmacol：2型糖尿病患者使用DPP-4i、GLP-1 RAs和SGLT-2i的骨折风险, objectType=article, longId=736722, objectId=3a36e36722e3, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=3a36e36722e3, replyNumber=0, likeNumber=55, createdTime=2022-11-24, rootId=0, userName=fmq_28614553, userId=0a3a2500014, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=3a36e36722e3, moduleTitle=Front Pharmacol：2型糖尿病患者使用DPP-4i、GLP-1 RAs和SGLT-2i的骨折风险, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=3a36e36722e3)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2081994, encodeId=abf9208199472, content=<a href='/topic/show?id=acf116218e6' target=_blank style='color:#2F92EE;'>#SGLT-2#</a>, objectTitle=Cardiovasc Diabetol：DPP-4抑制剂、GLP-1受体激动剂和SGLT-2抑制剂对心肾结局的影响, objectType=article, longId=723796, objectId=c62be2379617, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c62be2379617, replyNumber=0, likeNumber=46, createdTime=2022-08-25, rootId=0, userName=fmq_28614553, userId=0a3a2500014, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c62be2379617, moduleTitle=Cardiovasc Diabetol：DPP-4抑制剂、GLP-1受体激动剂和SGLT-2抑制剂对心肾结局的影响, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c62be2379617)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2081996, encodeId=0d06208199686, content=<a href='/topic/show?id=acf116218e6' target=_blank style='color:#2F92EE;'>#SGLT-2#</a>, objectTitle=重磅！SGLT-2抑制剂「恩格列净」在华获批，用于治疗射血分数保留的成人心力衰竭, objectType=article, longId=737405, objectId=2c50e37405f8, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=2c50e37405f8, replyNumber=0, likeNumber=44, createdTime=2023-02-09, rootId=0, userName=fmq_28614553, userId=0a3a2500014, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=2c50e37405f8, moduleTitle=重磅！SGLT-2抑制剂「恩格列净」在华获批，用于治疗射血分数保留的成人心力衰竭, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=2c50e37405f8)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2081997, encodeId=8311208199ed0, content=<a href='/topic/show?id=acf116218e6' target=_blank style='color:#2F92EE;'>#SGLT-2#</a>, objectTitle=磺脲类药物治疗2型糖尿病时若需添加SGLT-2抑制剂，可适当减少剂量以降低“低血糖”风险, objectType=article, longId=737027, objectId=7b6ee370276e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=7b6ee370276e, replyNumber=0, likeNumber=45, createdTime=2023-01-23, rootId=0, userName=fmq_28614553, userId=0a3a2500014, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=7b6ee370276e, moduleTitle=磺脲类药物治疗2型糖尿病时若需添加SGLT-2抑制剂，可适当减少剂量以降低“低血糖”风险, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=7b6ee370276e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2081992, encodeId=cafb20819925f, content=<a href='/topic/show?id=acf116218e6' target=_blank style='color:#2F92EE;'>#SGLT-2#</a>, objectTitle=Cardiovasc Diabetol：GLP-1激动剂 vs SGLT-2抑制剂 vs DPP-4抑制剂对T2DM患者心肾结局的影响, objectType=article, longId=301367, objectId=c4b830136e91, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c4b830136e91, replyNumber=0, likeNumber=43, createdTime=2022-04-05, rootId=0, userName=fmq_28614553, userId=0a3a2500014, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c4b830136e91, moduleTitle=Cardiovasc Diabetol：GLP-1激动剂 vs SGLT-2抑制剂 vs DPP-4抑制剂对T2DM患者心肾结局的影响, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c4b830136e91)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2081988, encodeId=a83b2081988d3, content=<a href='/topic/show?id=acf116218e6' target=_blank style='color:#2F92EE;'>#SGLT-2#</a>, objectTitle=Antioxidants ：GLP1-RA、SGLT-2i及其联合治疗12个月对2型糖尿病患者氧化和抗氧化生物标志物的影响, objectType=article, longId=219643, objectId=0933219643a0, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=0933219643a0, replyNumber=0, likeNumber=35, createdTime=2022-08-23, rootId=0, userName=fmq_28614553, userId=0a3a2500014, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=0933219643a0, moduleTitle=Antioxidants ：GLP1-RA、SGLT-2i及其联合治疗12个月对2型糖尿病患者氧化和抗氧化生物标志物的影响, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=0933219643a0)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2081993, encodeId=b82620819936c, content=<a href='/topic/show?id=acf116218e6' target=_blank style='color:#2F92EE;'>#SGLT-2#</a>, objectTitle=ACC/AHA/HFSA 2022：推荐SGLT-2抑制剂用于治疗心衰, objectType=article, longId=723398, objectId=d22be233981c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d22be233981c, replyNumber=0, likeNumber=48, createdTime=2022-05-24, rootId=0, userName=fmq_28614553, userId=0a3a2500014, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d22be233981c, moduleTitle=ACC/AHA/HFSA 2022：推荐SGLT-2抑制剂用于治疗心衰, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=d22be233981c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2081985, encodeId=3cca2081985fe, content=<a href='/topic/show?id=acf116218e6' target=_blank style='color:#2F92EE;'>#SGLT-2#</a>, objectTitle=JAMA Intern Med：SGLT-2抑制剂 vs磺脲类药物对II型糖尿病患者死亡风险的影响, objectType=article, longId=213849, objectId=4ba12138498f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=4ba12138498f, replyNumber=0, likeNumber=45, createdTime=2021-12-12, rootId=0, userName=fmq_28614553, userId=0a3a2500014, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=4ba12138498f, moduleTitle=JAMA Intern Med：SGLT-2抑制剂 vs磺脲类药物对II型糖尿病患者死亡风险的影响, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=4ba12138498f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2081989, encodeId=f1de20819893b, content=<a href='/topic/show?id=acf116218e6' target=_blank style='color:#2F92EE;'>#SGLT-2#</a>, objectTitle=Drugs：SGLT-2抑制剂在治疗非糖尿病性慢性肾病中的作用, objectType=article, longId=219863, objectId=fc9021986320, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=fc9021986320, replyNumber=0, likeNumber=39, createdTime=2022-06-02, rootId=0, userName=fmq_28614553, userId=0a3a2500014, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=fc9021986320, moduleTitle=Drugs：SGLT-2抑制剂在治疗非糖尿病性慢性肾病中的作用, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=fc9021986320)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2081987, encodeId=3c4f208198ea0, content=<a href='/topic/show?id=acf116218e6' target=_blank style='color:#2F92EE;'>#SGLT-2#</a>, objectTitle=Diabetes Obes Metab：SGLT-2抑制剂对T2DM患者血清尿酸水平的影响, objectType=article, longId=218712, objectId=149f218e125c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=149f218e125c, replyNumber=0, likeNumber=38, createdTime=2022-07-31, rootId=0, userName=fmq_28614553, userId=0a3a2500014, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=149f218e125c, moduleTitle=Diabetes Obes Metab：SGLT-2抑制剂对T2DM患者血清尿酸水平的影响, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=149f218e125c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2081991, encodeId=91b42081991ff, content=<a href='/topic/show?id=acf116218e6' target=_blank style='color:#2F92EE;'>#SGLT-2#</a>, objectTitle=BMJ子刊：SGLT-2抑制剂会造成肾损伤吗？这项2万多人的队列研究告诉你答案！, objectType=article, longId=292226, objectId=5d56292226bc, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=5d56292226bc, replyNumber=0, likeNumber=37, createdTime=2022-01-13, rootId=0, userName=fmq_28614553, userId=0a3a2500014, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=5d56292226bc, moduleTitle=BMJ子刊：SGLT-2抑制剂会造成肾损伤吗？这项2万多人的队列研究告诉你答案！, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=5d56292226bc)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2081990, encodeId=9f9b20819905a, content=<a href='/topic/show?id=acf116218e6' target=_blank style='color:#2F92EE;'>#SGLT-2#</a>, objectTitle=Diabetes Obes Metab：肾血流动力学对SGLT-2抑制剂的反应不依赖于蛋白质摄入量, objectType=article, longId=219913, objectId=119c21991317, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=119c21991317, replyNumber=0, likeNumber=44, createdTime=2022-07-12, rootId=0, userName=fmq_28614553, userId=0a3a2500014, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=119c21991317, moduleTitle=Diabetes Obes Metab：肾血流动力学对SGLT-2抑制剂的反应不依赖于蛋白质摄入量, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=119c21991317)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2081986, encodeId=45d5208198643, content=<a href='/topic/show?id=acf116218e6' target=_blank style='color:#2F92EE;'>#SGLT-2#</a>, objectTitle=降糖药SGLT-2抑制剂也能治心衰？看完本文马上掌握！, objectType=article, longId=214626, objectId=4e1d214626dd, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=4e1d214626dd, replyNumber=0, likeNumber=38, createdTime=2021-12-15, rootId=0, userName=fmq_28614553, userId=0a3a2500014, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=4e1d214626dd, moduleTitle=降糖药SGLT-2抑制剂也能治心衰？看完本文马上掌握！, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=4e1d214626dd)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2081984, encodeId=a032208198423, content=<a href='/topic/show?id=acf116218e6' target=_blank style='color:#2F92EE;'>#SGLT-2#</a>, objectTitle=BMJ：SGLT-2抑制剂或GLP-1受体激动剂治疗糖尿病的临床优势, objectType=article, longId=205766, objectId=c84a205e66fd, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c84a205e66fd, replyNumber=0, likeNumber=51, createdTime=2021-04-10, rootId=0, userName=fmq_28614553, userId=0a3a2500014, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c84a205e66fd, moduleTitle=BMJ：SGLT-2抑制剂或GLP-1受体激动剂治疗糖尿病的临床优势, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c84a205e66fd)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2081983, encodeId=dd882081983c4, content=<a href='/topic/show?id=acf116218e6' target=_blank style='color:#2F92EE;'>#SGLT-2#</a>, objectTitle=Diabetes Obes Metab：SGLT-2i与房颤的关系, objectType=article, longId=201708, objectId=479b201e089e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=479b201e089e, replyNumber=0, likeNumber=43, createdTime=2020-10-11, rootId=0, userName=fmq_28614553, userId=0a3a2500014, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=479b201e089e, moduleTitle=Diabetes Obes Metab：SGLT-2i与房颤的关系, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=479b201e089e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2081982, encodeId=f472208198247, content=<a href='/topic/show?id=acf116218e6' target=_blank style='color:#2F92EE;'>#SGLT-2#</a>, objectTitle=2019 日本建议：正确使用SGLT-2抑制剂, objectType=article, longId=184705, objectId=d6e2184e05d3, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d6e2184e05d3, replyNumber=0, likeNumber=43, createdTime=2020-09-14, rootId=0, userName=fmq_28614553, userId=0a3a2500014, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d6e2184e05d3, moduleTitle=2019 日本建议：正确使用SGLT-2抑制剂, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=d6e2184e05d3)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2081977, encodeId=afc220819e7d0, content=<a href='/topic/show?id=acf116218e6' target=_blank style='color:#2F92EE;'>#SGLT-2#</a>, objectTitle=ESH2018丨SGLT-2抑制剂对于合并糖尿病的高血压患者之影响, objectType=article, longId=140961, objectId=878d1409614b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=878d1409614b, replyNumber=0, likeNumber=45, createdTime=2018-10-24, rootId=0, userName=fmq_28614553, userId=0a3a2500014, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=878d1409614b, moduleTitle=ESH2018丨SGLT-2抑制剂对于合并糖尿病的高血压患者之影响, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=878d1409614b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2081976, encodeId=eb1320819e6bc, content=<a href='/topic/show?id=acf116218e6' target=_blank style='color:#2F92EE;'>#SGLT-2#</a>, objectTitle=Diabetes Obes Metab：SGLT-2抑制剂后来者居上长期疗效完胜DPP-4i和磺脲类, objectType=article, longId=139721, objectId=9b09139e213c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=9b09139e213c, replyNumber=0, likeNumber=44, createdTime=2019-03-13, rootId=0, userName=fmq_28614553, userId=0a3a2500014, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=9b09139e213c, moduleTitle=Diabetes Obes Metab：SGLT-2抑制剂后来者居上长期疗效完胜DPP-4i和磺脲类, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=9b09139e213c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2081980, encodeId=15a0208198086, content=<a href='/topic/show?id=acf116218e6' target=_blank style='color:#2F92EE;'>#SGLT-2#</a>, objectTitle=Diabetes Obes Metab：SGLT-2i增加2型糖尿病患者酮症酸中毒风险？, objectType=article, longId=148362, objectId=f0c914836230, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f0c914836230, replyNumber=0, likeNumber=49, createdTime=2018-12-15, rootId=0, userName=fmq_28614553, userId=0a3a2500014, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f0c914836230, moduleTitle=Diabetes Obes Metab：SGLT-2i增加2型糖尿病患者酮症酸中毒风险？, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f0c914836230)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

SGLT-2

2020-05-29

fmq_28614553 (审核中...)

前往app查看评论内容

#SGLT-2#

Cardiovasc Diabetol：GLP-1受体激动剂与SGLT-2抑制剂在2型糖尿病的有效性和安全性

2023-08-28

fmq_28614553 (审核中...)

前往app查看评论内容

#SGLT-2#

Front Pharmacol：2型糖尿病患者使用DPP-4i、GLP-1 RAs和SGLT-2i的骨折风险

2022-11-24

fmq_28614553 (审核中...)

前往app查看评论内容

#SGLT-2#

Cardiovasc Diabetol：DPP-4抑制剂、GLP-1受体激动剂和SGLT-2抑制剂对心肾结局的影响

2022-08-25

fmq_28614553 (审核中...)

前往app查看评论内容

#SGLT-2#

重磅！SGLT-2抑制剂「恩格列净」在华获批，用于治疗射血分数保留的成人心力衰竭

2023-02-09

fmq_28614553 (审核中...)

前往app查看评论内容

#SGLT-2#

磺脲类药物治疗2型糖尿病时若需添加SGLT-2抑制剂，可适当减少剂量以降低“低血糖”风险

2023-01-23

fmq_28614553 (审核中...)

前往app查看评论内容

#SGLT-2#

Cardiovasc Diabetol：GLP-1激动剂 vs SGLT-2抑制剂 vs DPP-4抑制剂对T2DM患者心肾结局的影响

2022-04-05

fmq_28614553 (审核中...)

前往app查看评论内容

#SGLT-2#

Antioxidants ：GLP1-RA、SGLT-2i及其联合治疗12个月对2型糖尿病患者氧化和抗氧化生物标志物的影响

2022-08-23

fmq_28614553 (审核中...)

前往app查看评论内容

#SGLT-2#

ACC/AHA/HFSA 2022：推荐SGLT-2抑制剂用于治疗心衰

2022-05-24

fmq_28614553 (审核中...)

前往app查看评论内容

#SGLT-2#

JAMA Intern Med：SGLT-2抑制剂 vs磺脲类药物对II型糖尿病患者死亡风险的影响

2021-12-12

fmq_28614553 (审核中...)

前往app查看评论内容

#SGLT-2#

Drugs：SGLT-2抑制剂在治疗非糖尿病性慢性肾病中的作用

2022-06-02

fmq_28614553 (审核中...)

前往app查看评论内容

#SGLT-2#

Diabetes Obes Metab：SGLT-2抑制剂对T2DM患者血清尿酸水平的影响

2022-07-31

fmq_28614553 (审核中...)

前往app查看评论内容

#SGLT-2#

BMJ子刊：SGLT-2抑制剂会造成肾损伤吗？这项2万多人的队列研究告诉你答案！

2022-01-13

fmq_28614553 (审核中...)

前往app查看评论内容

#SGLT-2#

Diabetes Obes Metab：肾血流动力学对SGLT-2抑制剂的反应不依赖于蛋白质摄入量

2022-07-12

fmq_28614553 (审核中...)

前往app查看评论内容

#SGLT-2#

降糖药SGLT-2抑制剂也能治心衰？看完本文马上掌握！

2021-12-15

fmq_28614553 (审核中...)

前往app查看评论内容

#SGLT-2#

BMJ：SGLT-2抑制剂或GLP-1受体激动剂治疗糖尿病的临床优势

2021-04-10

fmq_28614553 (审核中...)

前往app查看评论内容

#SGLT-2#

Diabetes Obes Metab：SGLT-2i与房颤的关系

2020-10-11

fmq_28614553 (审核中...)

前往app查看评论内容

#SGLT-2#

2019 日本建议：正确使用SGLT-2抑制剂

2020-09-14

fmq_28614553 (审核中...)

前往app查看评论内容

#SGLT-2#

ESH2018丨SGLT-2抑制剂对于合并糖尿病的高血压患者之影响

2018-10-24

fmq_28614553 (审核中...)

前往app查看评论内容

#SGLT-2#

Diabetes Obes Metab：SGLT-2抑制剂后来者居上长期疗效完胜DPP-4i和磺脲类

2019-03-13

fmq_28614553 (审核中...)

前往app查看评论内容

#SGLT-2#

Diabetes Obes Metab：SGLT-2i增加2型糖尿病患者酮症酸中毒风险？

2018-12-15

科室
- - 订阅+
  - 更多科室
工具
服务